Stockscreener 앱 받기
8.11
1.34%
-0.11
시간 외 거래:
8.11
전일 마감가:
$8.22
열려 있는:
$8.22
하루 거래량:
80,956
Relative Volume:
0.76
시가총액:
$116.93M
수익:
$166.88M
순이익/손실:
$-74.18M
주가수익비율:
-1.5996
EPS:
-5.07
순현금흐름:
$1.14M
1주 성능:
-6.13%
1개월 성능:
-26.14%
6개월 성능:
-54.41%
1년 성능:
-68.42%
1일 변동 폭
$8.08
$8.29
1주일 범위
$8.06
$8.825
52주 변동 폭
$7.8701
$26.99
Anika Therapeutics Inc Stock (ANIK) Company Profile
명칭
Anika Therapeutics Inc
전화
(781) 457-9000
주소
32 WIGGINS AVENUE, BEDFORD, MA
ANIK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
8.11 | 118.95M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
147.35 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.54 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.37 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.50 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | B. Riley Securities | Buy |
| 2024-11-01 | 재확인 | Barrington Research | Outperform |
| 2023-08-14 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | 재개 | Stephens | Equal-Weight |
| 2022-03-09 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | 개시 | Stephens | Overweight |
| 2021-07-16 | 개시 | UBS | Neutral |
| 2020-12-16 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | 업그레이드 | Sidoti | Neutral → Buy |
| 2020-01-10 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | 개시 | BWS Financial | Sell |
| 2019-09-24 | 재확인 | Barrington Research | Outperform |
| 2019-09-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | 업그레이드 | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | 다운그레이드 | Sidoti | Buy → Neutral |
| 2018-07-27 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | 재확인 | Barrington Research | Outperform |
| 2016-05-09 | 업그레이드 | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | 재확인 | Barrington Research | Outperform |
모두보기
Anika Therapeutics Inc 주식(ANIK)의 최신 뉴스
Ongoing Securities Investigation into Anika Therapeutics, Inc. (ANIK)Contact Levi & Korsinsky - ACCESS Newswire
Applying big data sentiment scoring on Anika Therapeutics Inc.Free Weekly Stock Watch With Growth Focus - Newser
Chart overlay techniques for tracking Anika Therapeutics Inc.3-Day Market Movement Forecast Analysis - Newser
Levi & Korsinsky Launches Fraud Investigation on Behalf of Anika Therapeutics, Inc. (ANIK) Shareholders - ACCESS Newswire
Can Anika Therapeutics Inc. hit a new high this monthShort-Term Trade Setup with Forecast Insight - Newser
Tools to assess Anika Therapeutics Inc.’s risk profileWeekly Market Direction and Sector Summary - Newser
What makes Anika Therapeutics Inc. stock price move sharplyMomentum Entry Alerts with Risk Control - Newser
Applying chart zones and confluence areas to Anika Therapeutics Inc.Free Real-Time Analysis With Entry Targets - Newser
How to manage a losing position in Anika Therapeutics Inc.High Reward Picks with Tight Risk Control - Newser
What’s the recovery path for long term holders of Anika Therapeutics Inc.Risk Managed Watchlist with Breakout Picks - Newser
Anika Therapeutics Inc. stock momentum explainedFree Buy Signal Based on Chart Analysis - Newser
Anika Therapeutics shares rise 2.77% after-hours following positive clinical trial results for Hyalofast. - AInvest
ATTENTION ANIK Shareholders: Lost Money on Anika Therapeutics, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Anika Therapeutics: Undervalued HA Platform with 2027 Catalysts - AInvest
Anika Therapeutics: Undervalued HA Platform With 2027 Catalysts (ANIK) - Seeking Alpha
Anika Therapeutics Inc. stock volume spike explainedFree Investment Strategy With Low Risk - Newser
Published on: 2025-08-06 20:31:06 - Newser
Levi & Korsinsky Investigates Anika Therapeutics, Inc. (ANIK) Over Possible Securities Fraud - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc.ANIK - PR Newswire
Anika Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Anika Therapeutics, Inc. (ANIK) - ACCESS Newswire
Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price Following 26% Dive - simplywall.st
Published on: 2025-08-05 23:20:00 - Newser
Combining machine learning predictions for Anika Therapeutics Inc.Free Swing Trading Plan With Smart Signals - Newser
Why Anika Therapeutics Inc. stock attracts strong analyst attentionFree Real Market Momentum Signal Generator - Newser
Anika Therapeutics Under Investigation for Securities Fraud and Misleading Investors. - AInvest
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Anika Therapeutics, Inc. (ANIK) - ACCESS Newswire
ANIKA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
ANIKA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
What are Anika Therapeutics Inc. company’s key revenue driversUnlock powerful stock screening for profits - Jammu Links News
What catalysts could drive Anika Therapeutics Inc. stock higher in 2025Maximize portfolio growth with strategic plans - Jammu Links News
Should I hold or sell Anika Therapeutics Inc. stock in 2025Exceptional return forecasts - Jammu Links News
When is Anika Therapeutics Inc. stock expected to show significant growthNavigate market volatility with smart strategies - Jammu Links News
How does Anika Therapeutics Inc. compare to its industry peersGet exclusive market analysis for investors - Jammu Links News
What are the latest earnings results for Anika Therapeutics Inc.Build a diversified portfolio for risk management - Jammu Links News
What institutional investors are buying Anika Therapeutics Inc. stockCapitalize on emerging trends for profits - Jammu Links News
Bank of New York Mellon Corp Sells 2,175 Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) - Defense World
Barrington Research Cuts Anika Therapeutics (NASDAQ:ANIK) Price Target to $15.00 - Defense World
Why is Anika Therapeutics Inc. stock attracting strong analyst attentionMaximize gains with expert trading strategies - Jammu Links News
Anika Therapeutics Q2 2025 Earnings Call: Strong Growth in Regenerative Solutions Revenue Amid Production Challenges and Missed Clinical Trial Endpoints. - AInvest
Kirby McInerney LLP Announces Investigation Against Anika Therapeutics, Inc. (ANIK) on Behalf of Investors - GlobeNewswire
Published on: 2025-08-01 22:12:39 - metal.it
Anika Therapeutics (ANIK) Receives a Buy from B.Riley Financial - The Globe and Mail
Anika Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Envestnet Asset Management Inc. Buys 26,557 Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) - Defense World
Anika slumps after trial setback for cartilage repair product - MSN
Anika Therapeutics shares rise 1.30% intraday after reporting considerable above-market revenue growth in H1 2025. - AInvest
Anika (ANIK) Q2 Revenue Beats by 4% - Nasdaq
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q2 2025 Earnings Call Transcript - Insider Monkey
Anika Therapeutics 2025 Q2 Earnings Misses Targets as Net Loss Widens 4411.4% - AInvest
Anika Therapeutics Inc (ANIK) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Anika Therapeutics Reports Q2 2025 Financial Results - TipRanks
Anika Therapeutics Inc (ANIK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.43%
0.47%
자본화:
|
볼륨(24시간):